Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C19H23NO5.ClH.H2O |
| Molecular Weight | 399.866 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.Cl.COC1=CC(C[C@@H]2NCCC3=CC(O)=C(O)C=C23)=CC(OC)=C1OC
InChI
InChIKey=NYRVBYLXLHGXDP-UTLKBRERSA-N
InChI=1S/C19H23NO5.ClH.H2O/c1-23-17-7-11(8-18(24-2)19(17)25-3)6-14-13-10-16(22)15(21)9-12(13)4-5-20-14;;/h7-10,14,20-22H,4-6H2,1-3H3;1H;1H2/t14-;;/m0../s1
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C19H23NO5 |
| Molecular Weight | 345.3896 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | H2O |
| Molecular Weight | 18.0153 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including:
http://www.situsobat.com/2014/04/inolin-tablet-3-mg.html
www.drugfuture.com/mt/tretoquinol-hydrochloride.pdf
Curator's Comment: description was created based on several sources, including:
http://www.situsobat.com/2014/04/inolin-tablet-3-mg.html
www.drugfuture.com/mt/tretoquinol-hydrochloride.pdf
Trimetoquinol hydrochloride dilates bronchial muscle selectively by stimulating Beta 2-receptors. It is used for the relief of bronchoconstriction associated with bronchitis, asthmatic bronchitis and bronchial asthma. Since the concurrent use of the drug with catecholamines such as Epinephrine and Isoproterenol may induce arrythmia or cardiac arrest in some cases, concurrent use is not recommended. Adverse reactions : Palpitation may occur occasionally, and alteration of blood pressure and precordial pain may appear rarely; headache may occur occasionally; tremor, dizziness, feverish sensation may also be encountered in a rare incidence; occasionally, nausea and anorexia may appear.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
| 7.34 null [pKi] | |||
Target ID: CHEMBL213 Sources: http://www.ncbi.nlm.nih.gov/pubmed/10525112 |
6.49 null [pKi] | ||
Target ID: CHEMBL246 Sources: http://www.ncbi.nlm.nih.gov/pubmed/10525112 |
5.43 null [pKi] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | Inolin Approved UseIt is given as the bronchodilating agent in the management of reversible airways obstruction, as in asthma. |
|||
Sources: www.drugfuture.com/mt/tretoquinol-hydrochloride.pdf |
Palliative | Inolin Approved UseIt is given as the bronchodilating agent in the management of reversible airways obstruction, as in chronic obstructive pulmonary disease. |
||
| Palliative | Inolin Approved UseIt is used to treat chronic bronchitis. |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Errors in opioid prescribing: a prospective survey in cancer pain. | 2010-04 |
|
| Eyelid localization in mantle cell lymphoma: long-lasting complete remission after surface brachytherapy. | 2009-08-20 |
|
| Plasma and urinary concentrations of trimetoquinol by LC-MS-MS following intravenous and intra-tracheal administration to horses with heaves. | 2008-12 |
|
| The effect of botulinum toxin type A on full-face intense pulsed light treatment: a randomized, double-blind, split-face study. | 2008-08 |
|
| [Yersinia psuedotuberculosis septicemia in a healthy young woman]. | 2008-03 |
|
| Identification and characterization of a novel peptide ligand of Tie2 for targeting gene therapy. | 2008-03 |
|
| Trimetoquinol: bronchodilator effects in horses with heaves following aerosolised and oral administration. | 2007-05 |
|
| Intravenous and intratracheal administration of trimetoquinol, a fast-acting short-lived bronchodilator in horses with 'heaves'. | 2006-11 |
|
| Endoscopic video-assisted breast surgery: procedures and short-term results. | 2006-08 |
|
| 1-Benzyl-1,2,3,4-tetrahydroisoquinoline-6,7-diols as novel affinity and photoaffinity probes for beta-adrenoceptor subtypes. | 2006-03-15 |
|
| Long term results after transpupillary thermotherapy in eyes with occult choroidal neovascularisation associated with age related macular degeneration: a prospective trial. | 2006-02 |
|
| Single-incision, minimally invasive total hip arthroplasty: length doesn't matter. | 2004-12 |
|
| Beta-adrenoreceptor agonists for diffuse esophageal spasm. | 2002 |
|
| Biochemical activities of trimetoquinol analogs at human beta(1)- and beta(3)-adrenergic receptors. | 2001-01 |
|
| Bronchodilators for the prevention and treatment of chronic lung disease in preterm infants. | 2001 |
Sample Use Guides
In Vivo Use Guide
Curator's Comment: Intravenous and intratracheal administration of trimetoquinol are tested also:
http://www.ncbi.nlm.nih.gov/pubmed/17124848
http://www.ncbi.nlm.nih.gov/pubmed/17124848
http://www.ncbi.nlm.nih.gov/pubmed/963963
http://www.ncbi.nlm.nih.gov/pubmed/971582
3-12 mg per day (in 2-3 separate doses)
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/667443
Pre-incubation of platelet microsomes with Trimethoquinol (10-100 ug/ml) for up to 4 min didn’t suppress production of Thromboxane A2-like activity.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:12:19 GMT 2025
by
admin
on
Mon Mar 31 19:12:19 GMT 2025
|
| Record UNII |
SS28YGI1ZQ
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID10222852
Created by
admin on Mon Mar 31 19:12:19 GMT 2025 , Edited by admin on Mon Mar 31 19:12:19 GMT 2025
|
PRIMARY | |||
|
288748
Created by
admin on Mon Mar 31 19:12:19 GMT 2025 , Edited by admin on Mon Mar 31 19:12:19 GMT 2025
|
PRIMARY | |||
|
SS28YGI1ZQ
Created by
admin on Mon Mar 31 19:12:19 GMT 2025 , Edited by admin on Mon Mar 31 19:12:19 GMT 2025
|
PRIMARY | |||
|
72534-66-8
Created by
admin on Mon Mar 31 19:12:19 GMT 2025 , Edited by admin on Mon Mar 31 19:12:19 GMT 2025
|
PRIMARY | |||
|
SUB15598MIG
Created by
admin on Mon Mar 31 19:12:19 GMT 2025 , Edited by admin on Mon Mar 31 19:12:19 GMT 2025
|
PRIMARY | |||
|
CHEMBL299175
Created by
admin on Mon Mar 31 19:12:19 GMT 2025 , Edited by admin on Mon Mar 31 19:12:19 GMT 2025
|
PRIMARY | |||
|
23724963
Created by
admin on Mon Mar 31 19:12:19 GMT 2025 , Edited by admin on Mon Mar 31 19:12:19 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE | |||
|
ANHYDROUS->SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |